News
The FDA has extended the review period for the NDA for aficamten for the treatment of patients with obstructive hypertrophic cardiomyopathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback